A Prospective Longitude Study of Lecanemab in Early Alzheimer's Disease: 6‐month follow up

Abstract

Background: Alzheimer's disease (AD) prevalence is expected to rise dramatically due to rapidly aging populations. Alzheimer's disease pathology is triggered by the accumulation of soluble and insoluble aggregated Aβ peptides (oligomers, protofibrils, and fibrils).

The paper